

Globalization of clinical trials: Giving more patients access to cancer therapies at the point of clinical decision making

Today's clinical research world requires diverse patient populations and a global reach to deliver to the timelines required. Fortrea is on a quest every day to find the right country and site for achieving this goal for your study. Fortrea understands these needs, exploring new regions and countries is what we do to give you the right options.

Large enough to serve, engaged enough to care!

Fortrea supports our sponsors with a team of 50+ oncologists who employ a collaborative approach, which can result in co-authorship of peer-reviewed journal articles based on projects we've supported. In addition, they have contributed to industry knowledge via articles about their own academic and collaborative work.



2025

Number	Authors, Title, Journal
2025.1	<p>Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorria T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: Results from the Pembro-real 5Y global registry. <i>Journal for ImmunoTherapy of Cancer.</i> February 2025. https://jitc.bmj.com/content/13/2/e010674.long</p> <p>Summary: This real-world global registry study (Pembro-real 5Y) evaluated long-term outcomes of patients with advanced NSCLC and PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials and found that durable survival seen in pivotal studies is achievable in routine practice. Among more than 1,000 patients across 14 countries, the five-year overall survival rate was ~27%, with outcomes closely mirroring KEYNOTE-024 in a trial-like subcohort. Performance status emerged as the strongest determinant of long-term survival, followed by age and level of PD-L1 expression, highlighting that patient selection—rather than treatment setting—largely drives long-term benefit from pembrolizumab monotherapy.</p>

2024

Number	Authors, Title, Journal
2024.1	<p>Mankan AK, Shankar A, Limaye S, Ajaikumar BS, Nachane P, Singh N, Dawkhar S, Batra U, Bhosekar A, Ganguly S, Gawli P, Debnath K, Padalalu V, Reddy P, Sundaramoorthi S, Naveen KK, Bondarde S, Kumar P, Davis S, Ramkissoon S, Chacko RT, Vidal L, Chico I, Hegedus A, Gupta S, Saini KS. Cancer trials ecosystem in India – ready for prime time? <i>JCO Global Oncology.</i> June 2024. https://ascopubs.org/doi/full/10.1200/GO.23.00405</p> <p>Summary: This paper reviews the evolving cancer trials ecosystem in India, highlighting its potential as a prime location for global oncology clinical trials. It discusses the advantages India offers, such as a large and diverse patient pool, relatively low costs and well-trained healthcare professionals. The authors also address challenges, including regulatory shifts and infrastructure limitations, while emphasizing recent improvements in India’s clinical trial regulations. By analyzing these factors, the study underscores India’s readiness to play a significant role in advancing global cancer research and therapeutic development.</p>



2023

Number	Authors, Title, Journal
2023.1	<p>Dlamini Z, Molefi T, Khanyile R, Mkhabele M, Damane B, Kokoua A, Bida M, Saini KS, Chauke-Malinga N, Luvhengo TE, Hull R. From incidence to intervention: A comprehensive look at breast cancer in South Africa. <i>Oncology & Therapy</i>. November 2023. https://doi.org/10.1007/s40487-023-00248-1</p> <p>Summary: This paper summarizes the growing burden of breast cancer in South Africa, emphasizing the stark disparities in screening, treatment, and survival across ethnic and socioeconomic groups. The incidence of breast cancer has been rising, with some communities experiencing delays in diagnosis due to ongoing challenges in healthcare access and equity. The co-occurrence of breast cancer and HIV further complicates care, particularly for the Black population. To address these challenges, the paper advocates for robust screening programs targeting marginalized communities, faster treatment initiation, and HIV-sensitive interventions. It calls for pan-African collaboration and tailored strategies to improve breast cancer outcomes across the continent.</p>

2020

Number	Authors, Title, Journal
2020.1	<p>Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A. Reimagining global oncology clinical trials for the postpandemic era: A call to arms. <i>JCO Global Oncology</i>. September 2020. https://doi.org/10.1200/GO.20.00346</p> <p>Summary: This perspective paper argues that lessons from the COVID-19 pandemic should permanently reshape global oncology clinical trials. The authors call for more patient-centric, technology-enabled and operationally streamlined trial designs to improve access, efficiency and resilience without compromising scientific rigor.</p>



See a full list of Fortrea oncology publications starting in 2020.

LEARN MORE at fortrea.com